AstraZeneca said the FDA pushed back its decision on camizestrant, its oral selective estrogen receptor degrader (SERD), after an FDA advisory committee voted against approval for a first-line use setting in advanced breast cancer. The delay follows negative adcomm feedback related to the SERENA-6 Phase 3 program’s design, lack of survival data, and questions around quality-of-life effects.